Table 1 Patients’ demographic information

Age

Wilcoxon signed-rank

0.4175

 Median (IQR)

67 (58, 75)

67 (59, 74)

Sex

Chi-square

0.8305

 Female

918 (20.80)

202 (21.11)

 Male

3496 (79.20)

755 (78.89)

Pathology

Chi-square

0.1929

 8000/3: Neoplasm, malignant

7 (0.16)

2 (0.21)

 8010/3: Carcinoma, NOS

49 (1.11)

6 (0.63)

 8013/3: Large cell neuroendocrine carcinoma

5 (0.11)

3 (0.31)

 8020/3: Carcinoma, undifferentiated, NOS

4 (0.09)

2 (0.21)

 8021/3: Carcinoma, anaplastic, NOS

1 (0.02)

0 (0)

 8032/3: Spindle cell carcinoma, NOS

1 (0.02)

0 (0)

 8041/3: Small cell carcinoma, NOS

6 (0.14)

1 (0.10)

 8044/3: Small cell carcinoma, intermediate cell

0 (0)

1 (0.10)

 8045/3: Combined small cell carcinoma

2 (0.05)

0 (0)

 8046/3: Non-small cell carcinoma

2 (0.05)

0 (0)

 8051/3: Verrucous carcinoma, NOS

0 (0)

1 (0.10)

 8070/3: Squamous cell carcinoma, NOS

86 (1.95)

22 (2.30)

 8071/3: Squamous cell carcinoma, keratinizing, NOS

9 (0.20)

0 (0)

 8072/3: Squamous cell carcinoma, large cell, nonkeratinizing, NOS

2 (0.05)

0 (0)

 8140/3: Adenocarcinoma, NOS

3103 (70.30)

689 (72.00)

 8142/3: Linitis plastica

3 (0.07)

0 (0)

 8144/3: Adenocarcinoma, intestinal type

237 (5.37)

38 (3.97)

 8145/3: Carcinoma, diffuse type

50 (1.13)

12 (1.25)

 8210/3: Adenocarcinoma in adenomatous polyp

25 (0.57)

4 (0.42)

 8211/3: Tubular adenocarcinoma

21 (0.48)

1 (0.10)

 8240/3: Carcinoid tumor, NOS

24 (0.54)

11 (1.15)

 8244/3: Mixed adenoneuroendocrine carcinoma

2 (0.05)

1 (0.10)

 8246/3: Neuroendocrine carcinoma, NOS

33 (0.75)

10 (1.04)

 8255/3: Adenocarcinoma with mixed subtypes

69 (1.56)

15 (1.57)

 8260/3: Papillary adenocarcinoma, NOS

6 (0.14)

0 (0)

 8261/3: Adenocarcinoma in villous adenoma

1 (0.02)

0 (0)

 8263/3: Adenocarcinoma in tubulovillous adenoma

6 (0.14)

0 (0)

 8310/3: Clear cell adenocarcinoma, NOS

1 (0.02)

0 (0)

 8323/3: Mixed cell adenocarcinoma

2 (0.05)

0 (0)

 8480/3: Mucinous adenocarcinoma

79 (1.79)

16 (1.67)

 8481/3: Mucin-producing adenocarcinoma

23 (0.52)

3 (0.31)

 8490/3: Signet ring cell carcinoma

408 (9.24)

90 (9.40)

 8510/3: Medullary carcinoma, NOS

1 (0.02)

0 (0)

 8512/3: Medullary carcinoma with lymphoid stroma

1 (0.02)

1 (0.10)

 8560/3: Adenosquamous carcinoma

32 (0.72)

5 (0.52)

 8574/3: Adenocarcinoma with neuroendocrine differentiation

9 (0.20)

0 (0)

 8936/3: Gastrointestinal stromal sarcoma

104 (2.36)

22 (2.30)

 8980/3: Carcinosarcoma, NOS

0 (0)

1 (0.10)

T

Chi-square

0.6922

 T1

486 (11.01)

94 (9.82)

 T1a

421 (9.54)

102 (10.66)

 T1b

410 (9.29)

83 (8.67)

 T2

593 (13.43)

123 (12.85)

 T3

2091 (47.37)

464 (48.48)

 T4

54 (1.22)

12 (1.25)

 T4a

199 (4.51)

37 (3.87)

 T4b

160 (3.62)

42 (4.39)

N

Chi-square

0.3275

 N0

1928 (43.68)

436 (45.56)

 N1

1612 (36.52)

340 (35.53)

 N2

541 (12.26)

123 (12.85)

 N3

333 (7.54)

58 (6.06)

M

Chi-square

0.3149

 M0

3530 (79.97)

779 (81.40)

 M1

884 (20.03)

178 (18.60)

Stage

Chi-square

0.1895

 I

18 (0.41)

8 (0.84)

 IA

600 (13.59)

128 (13.38)

 IB

395 (8.95)

92 (9.61)

 II

18 (0.41)

0 (0)

 IIA

136 (3.08)

30 (3.13)

 IIB

759 (17.20)

170 (17.76)

 IIIA

849 (19.23)

190 (19.85)

 IIIB

342 (7.75)

87 (9.09)

 IIIC

412 (9.33)

74 (7.73)

 IV

885 (20.05)

178 (18.60)

Size (mm)

Wilcoxon signed-rank

0.8093

 Median (IQR)

40 (22, 55)

40 (20, 55)

Surgery

Chi-square

0.1010

 No

1810 (41.01)

420 (43.89)

 Yes

2604 (58.99)

537 (56.11)

Radiotherapy

Chi-square

0.0069**

 No

2242 (50.79)

440 (45.98)

 Yes

2172 (49.21)

517 (54.02)

Chemotherapy

Chi-square

0.1061

 No

1485 (33.64)

296 (30.93)

 Yes

2929 (66.36)

661 (69.07)

History of malignancy

Chi-square

0.1407

 No

3574 (80.97)

755 (78.89)

 Yes

840 (19.03)

202 (21.11)